13F Data
13F filer · CIK 2106939

PSP Research LLC

LAS VEGAS, NV · filing since Q4 2025 · last filing Oct 21, 2026
Reported value
$145.8M
$-42.1M vs prior
Positions
44
New / sold out
1 / 32
Added / reduced
0 / 27
Turnover
3.0%
buys $5.0M · sells $46.0M
Top-10 weight
95.0%

Biggest buys vs Q2 2026

ChangeSecurityShares changeChange %Est. trade value
NewSERA PROGNOSTICS INC+2,396,685–+$5.0M

Biggest sells vs Q2 2026

ChangeSecurityShares changeChange %Est. trade value
ReducedSPDR SERIES TRUST-183,500-32.2%$-28.9M
Sold outDISC MEDICINE INC-8,000-100.0%$-585.1K
Sold outRAPPORT THERAPEUTICS INC-14,000-100.0%$-583.4K
Sold outULTRAGENYX PHARMACEUTICAL IN-17,000-100.0%$-567.6K
Sold outMONTE ROSA THERAPEUTICS INC-23,000-100.0%$-556.6K
Sold outIONIS PHARMACEUTICALS INC-6,800-100.0%$-539.2K
Sold outPHARVARIS N V-15,000-100.0%$-518.7K
Sold outACADIA PHARMACEUTICALS INC-19,766-100.0%$-500.1K
Sold outPTC THERAPEUTICS INC-6,000-100.0%$-489.4K
Sold outCELLDEX THERAPEUTICS INC NEW-13,000-100.0%$-483.7K
49 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2025: $114.4MQ1 2026: $141.3MQ2 2026: $187.9MQ3 2026: $145.8M
Q4 2025Q3 2026

Holdings · Q3 2026

#SecuritySharesValueWeight
1ISHARES TR0-3 MTH TREASURY700,000$70.5M48.33%
2SPDR SERIES TRUSTST STR SP BIOT386,500$60.9M41.79%
3SERA PROGNOSTICS INCCLASS A COM2,396,685$5.0M3.43%
4HALOZYME THERAPEUTICS INCCOM3,000$331.2K0.23%
5MADRIGAL PHARMACEUTICALS INCCOM600$302.4K0.21%
6EXELIXIS INCCOM5,000$292.1K0.20%
7ROYALTY PHARMA PLCSHS CLASS A5,000$291.8K0.20%
8ARGENX SESPONSORED ADR300$287.7K0.20%
9NURIX THERAPEUTICS INCCOM12,000$284.5K0.20%
10TG THERAPEUTICS INCCOM5,000$278.9K0.19%
34 more rows. Subscribe for $29/month to see every row, download the data and use the API.